MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023

Travere Therapeutics (TVTX): A Closer Look at the -24.37% Monthly Descent in the Biotechnology Realm

Embark on an enlightening exploration of Travere Therapeutics (TVTX) as we unravel the mysteries behind its substantial -24.37% descent, with shares plunging to $16.45. In this blog post, we delve into the world of the Biotechnology Industry, shedding light on the factors that contributed to TVTX's downturn. Join us as we dissect the story of Travere Therapeutics and gain a deeper understanding of the intricacies within the ever-evolving biotech landscape.

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

Understanding the Biotechnology Industry: Before delving into TVTX's performance, let's first grasp the broader context of the Biotechnology Industry. Our analysis of 959 stocks within this sector reveals that 61.23% exhibited an Uptrend, while 38.77% experienced a Downtrend. This comprehensive industry overview serves as the backdrop for uncovering the unique challenges and opportunities faced by TVTX amidst the dynamic and competitive biotech landscape.

Factors Influencing TVTX's Descent: Multiple factors may have contributed to the significant -24.37% monthly descent of Travere Therapeutics. The biotech realm is notorious for its inherent risks and uncertainties, including clinical trial outcomes, regulatory dynamics, and market fluctuations. By examining these factors, we aim to shed light on the intricacies that led to TVTX's descent, equipping investors with valuable insights and a deeper understanding of the biotech terrain.

Navigating the Biotech Landscape: As investors evaluate the implications of TVTX's descent, navigating the complex and ever-evolving biotech landscape becomes paramount. Identifying promising therapeutic areas, assessing pipeline progress, and staying informed about regulatory milestones are essential steps in making informed investment decisions. This blog post offers a comprehensive analysis to help investors navigate the challenges and opportunities within the dynamic biotech market.

Opportunities and Risks in Biotech: While TVTX experienced a significant descent, it's crucial to acknowledge that the biotech industry presents both opportunities and risks. The pursuit of groundbreaking treatments, advancements in scientific research, and potential market expansions offer glimpses of growth. However, investors must also be aware of the inherent risks associated with clinical trials, regulatory hurdles, and intense competition. This blog post aims to shed light on the opportunities and risks within the biotech industry, empowering investors to make informed decisions.

Travere Therapeutics' -24.37% monthly descent shines a spotlight on the dynamic nature of the Biotechnology Industry and the challenges faced by companies operating within this sector. By analyzing market trends, understanding the factors influencing TVTX's performance, and identifying potential opportunities, investors can navigate the biotech market with greater confidence. It's essential to conduct thorough research and seek advice from qualified financial professionals before making any investment decisions.

Related Ticker: TVTX

Aroon Indicator for TVTX shows an upward move is likely

TVTX's Aroon Indicator triggered a bullish signal on November 28, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 28, 2025. You may want to consider a long position or call options on TVTX as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TVTX moved out of overbought territory on November 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for TVTX turned negative on November 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TVTX broke above its upper Bollinger Band on October 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (43.103) is normal, around the industry mean (27.168). P/E Ratio (0.000) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (7.102) is also within normal values, averaging (334.447).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 58 to 110.02B. VRTX holds the highest valuation in this group at 110.02B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 73%. KTTA experienced the highest price growth at 403%, while CLSD experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -61% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 93
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
TVTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. TVTX showed earnings on October 30, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which develops pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3611 Valley Centre Drive
Phone
+1 888 969-7879
Employees
380
Web
https://www.travere.com
Interact to see
Advertisement
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#investment#artificial_intelligence
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#artificial_intelligence#trading
Tickeron, a leader in AI-powered financial solutions, proudly announces the launch of its Double Agent Trading Bot, designed for trading Carpenter Technology Corporation (CRS) and Direxion Daily Semiconductor Bear 3x Shares (SOXS).
#artificial_intelligence
Apple Inc. (AAPL), a global leader in consumer electronics, continues to be a cornerstone of the technology sector, driving innovation and commanding significant market attention.
#artificial_intelligence
NVIDIA’s earnings on May 28 could jolt the tech sector. With market volatility rising, traders are turning to Tickeron’s AI Agent for real-time insights, predictive analytics, and dual-strategy trading tools to navigate potential price swings and seize market opportunities.
#artificial_intelligence
As the DOJ and FTC move to break up Google’s search dominance and impose AI investment oversight, the tech giant faces a pivotal legal battle that could reshape the digital and AI landscapes—creating major implications for investors, competitors, and consumers alike.
#artificial_intelligence
GameStop (GME) continues to captivate investors with its explosive volatility and strong retail sentiment. As AI tools highlight bullish signals and a possible breakout, traders weigh the risks of speculation against the potential rewards in May 2025.
#artificial_intelligence
Mastercard (MA) continues to impress investors with strong earnings, rising digital payments, and bullish AI-driven signals. Backed by robust financials and cutting-edge trading tools from Tickeron, MA stands out as a leader in the fintech space for 2025.
From Walmart's retail resilience to Exxon Mobil's energy strength, May 2025 highlights key market movers. Discover how Tickeron’s AI bots analyze WMT, IVW, COST, and XOM—uncovering trends, boosting trading strategies, and navigating market volatility with precision.
#trading#artificial_intelligence
A powerful recession signal is flashing red: the Leading/Lagging Ratio has plunged to levels not seen since 2008. As markets grow turbulent, smart investors are turning to Tickeron’s AI trading agents to spot opportunities and stay ahead of the downturn.
#trading#artificial_intelligence
AI trading bots are no longer just experimental—they’re outperforming traditional strategies. Discover how bots trading ITA, TSM, META, and others achieved over 40% annual returns and what this means for the future of investing.
FingerMotion (FNGR) is making waves in 2025 with a 52% stock surge, strategic AI expansion into Indonesia, and strong retail momentum. Learn how traders are using correlation analysis, inverse ETFs, and Tickeron’s AI tools to navigate FNGR’s dynamic moves.
#artificial_intelligence#trading
Ferrari (RACE) is accelerating in 2025 with a 25% YTD gain, strong earnings, and bullish momentum fueled by innovation and Lewis Hamilton’s F1 move. Discover how Tickeron’s AI tools help traders capitalize on this luxury stock’s high-performance potential.
Intel’s stock is down 64%, but a bold turnaround under new CEO Lip-Bu Tan and the upcoming 18A chip rollout could spark a rebound. This article explores Intel’s financials, strategic shifts, and how AI tools from Tickeron help traders navigate the volatility.
#artificial_intelligence
Dogecoin (DOGE) fell 12.78% in five days, rattled by whale activity, Musk headlines, and ETF rumors. Is a breakout coming—or more downside? Explore key trends, technical levels, and how Tickeron’s AI bots help traders navigate DOGE’s next move.
The week of June 2-6, 2025, saw financial markets demonstrate resilience amid U.S.-China trade tensions and key economic data releases.
Tesla, Inc. (TSLA), a global leader in electric vehicles (EVs) and artificial intelligence (AI)-driven technologies, has been a focal point for investors in 2025.
#artificial_intelligence#trading
As artificial intelligence continues to reshape the financial industry, AI-powered trading agents have emerged as influential tools in portfolio management and speculative trading.
#investment#artificial_intelligence
Amazon (NASDAQ: AMZN) remains a cornerstone of the technology and e-commerce sectors, consistently driving innovation and market influence.
#artificial_intelligence
ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…